Milestone Pharmaceuticals Announces Clinical Data Presentations at Upcoming Cardiology Conferences
Key Highlights
- ➤Milestone will present CARDAMYST and etripamil data at three cardiovascular conferences
- ➤Etripamil remains in Phase 3 development for adult AFib-RVR control
- ➤Etripamil remains in Phase 2 development for pediatric PSVT treatment
- ➤CARDAMYST is FDA-approved for acute symptomatic PSVT conversion in adults
MONTREAL and CHARLOTTE, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that data and program updates for CARDAMYST® (etripamil) nasal spray for its approved PSVT indication and on etripamil nasal spray for an investigational indication will be presented at three upcoming cardiovascular medical meetings: * Cardiology Advanced Practice Providers (CAPP) National Conference (October 22-24) * Transcatheter Cardiovascular Therapeutics (TCT) 2026 (October 31-November 3) * American Heart Association (AHA) Scientific Sessions 2026 (November 6-9) Presentation Details
Cardiology Advanced Practice Providers (CAPP) National Conference Title: Minimal Blood Pressure Effects of Intranasal Etripamil for PSVT Presenter: Adriane Atkins, ND, Milestone Pharmaceuticals Day/Time: Thursday, October 22, 6:45 pm CT Location: Hyatt Regency Dallas, Dallas, TX
Get started
Create a free account to read the full story.